avidity assay measures how tightly IgG antibodies bind to the parasite. Early after infection, IgG antibodies are “low‑avidity,” meaning they detach easily. As weeks pass, the immune system refines these antibodies, increasing avidity. A high‑avidity result therefore points to an infection that likely occurred more than three to four months ago—often before conception—while a low‑avidity result suggests a recent infection that may still be active.
How the test is done: A blood sample is drawn and sent to a laboratory that performs an enzyme‑linked immunosorbent assay (ELISA) with a chaotropic agent that disrupts weak antibody‑antigen bonds. The percentage of antibodies that remain bound is reported as an avidity index. Most labs use a cutoff of 30 %: values above this are considered high avidity, below are low.
Interpretation guidelines (per CDC and ACOG):
- Low avidity (<30 %): Recent infection (< 12 weeks). Requires PCR testing and close ultrasound follow‑up.
- Intermediate avidity (30‑40 %): Ambiguous timing. Often combined with clinical history and repeat testing.
- High avidity (≥40 %): Infection likely occurred before pregnancy; fetal risk is low, but clinicians may still monitor.
Because avidity testing is highly specific—studies report specificity > 95 %—it is a reliable tool for narrowing the window of infection. However, false‑low avidity can occur in immunocompromised patients, and some labs report a small percentage of low‑avidity results in women with chronic infection. That’s why avidity is always paired with PCR and ultrasound for a comprehensive assessment.
In practice, many clinicians repeat the avidity test four weeks after an initial low result. A rising avidity index can reassure both provider and patient that the infection is moving into the later, less risky phase. The trend also helps decide whether to start antiparasitic therapy now or wait until later in pregnancy.
PCR testing for toxoplasmosis: how it works and what it detects
Polymerase chain reaction (PCR) amplifies tiny fragments of DNA, allowing clinicians to detect T. gondii genetic material directly in amniotic fluid. Unlike antibody tests, PCR does not rely on the mother’s immune response; it shows whether the parasite is present in the fetal environment.
Procedure: Around 16–18 weeks gestation (or later if IgM remains positive), an obstetrician performs amniocentesis under ultrasound guidance. A small amount of amniotic fluid (about 20 ml) is withdrawn and sent to a reference laboratory. The PCR assay targets the B1 gene, a highly conserved region of the parasite’s genome, and can detect as few as 10 copies of DNA per milliliter.
What PCR tells you:
- Positive PCR: Confirms fetal infection. Management may include antiparasitic therapy (spiramycin or pyrimethamine‑sulfadiazine) and more frequent ultrasounds.
- Negative PCR: Does not completely rule out infection; the parasite might be present below the detection threshold, especially if the amniocentesis was performed early.
According to the CDC, PCR sensitivity for detecting fetal infection in amniotic fluid ranges from 90 % to 95 % when performed after 18 weeks, with specificity exceeding 98 %. These numbers make PCR the gold standard for confirming congenital toxoplasmosis, but the invasive nature of amniocentesis means clinicians weigh the benefits against procedural risks.
For women who cannot undergo amniocentesis, some centers offer PCR on cord blood after delivery, though this approach is less sensitive for early‑gestation infections. Your care team will discuss the safest sampling option based on your gestational age and overall health.
Ultrasound surveillance after a positive IgM: schedule and what you’ll see
Ultrasound is the non‑invasive window into fetal development. After a positive IgM—and especially after a low‑avidity or positive PCR result—guidelines recommend a series of targeted scans to monitor for signs of toxoplasmosis.
Typical surveillance timeline (based on ACOG and NICE recommendations):
- First scan (18–20 weeks): Baseline anatomy survey. Look for intracranial calcifications, hydrocephalus, hepatosplenomegaly, and placental thickening.
- Follow‑up scans (every 4 weeks until 30 weeks): Focused neurosonography to detect evolving brain lesions, and growth measurements to catch intrauterine growth restriction.
- Late‑gestation scan (34–36 weeks): Final assessment before delivery; confirms resolution or progression of any abnormalities.
During each scan, the sonographer will assess head circumference, ventricular size, brain echogenicity, placental appearance, and fetal growth curves. If an abnormality appears, the team may add fetal MRI for higher‑resolution imaging of brain structures.
Most parents find the “watchful waiting” period stressful. It helps to schedule scans at the same clinic, ask for a consistent sonographer, and keep a notebook of measurements. Knowing what the technician is looking for—such as subtle bright spots that could be calcifications—can make the experience feel less like a mystery.
When ultrasound findings are equivocal, some tertiary centers add fetal magnetic resonance imaging (MRI). MRI can clarify subtle brain lesions that are hard to see on ultrasound, offering another layer of reassurance—or a clearer indication for intervention.
Interpreting results: false positives, false negatives, and what they mean
No test is perfect. Understanding the limitations of IgM, avidity, and PCR helps you avoid unnecessary anxiety.
False‑positive IgM: Certain autoimmune conditions (e.g., rheumatoid factor) and technical cross‑reactivity can produce a positive IgM without true infection. In such cases, avidity is usually high, and PCR is negative. Re‑testing after a few weeks or using a different assay can clarify the result.
False‑negative IgM: Early infection—within the first week—may not yet have generated detectable antibodies. If you have a known exposure—say, a stray cat bite or undercooked meat—your provider may still order avidity and PCR based on clinical suspicion.
Avidity pitfalls: Low avidity is highly suggestive of recent infection, but a small subset of women with chronic infection can exhibit low avidity due to assay variability. That’s why avidity is interpreted alongside PCR and ultrasound findings.
PCR limitations: A negative PCR does not guarantee a toxin‑free fetus, especially if the amniocentesis was performed before 18 weeks. In such cases, clinicians may repeat PCR later or rely more heavily on serial ultrasounds.
Overall, the combination of these three tools—IgM, avidity, and PCR—creates a diagnostic net that catches most true infections while reducing false alarms. Your care team will synthesize the data, your exposure history, and any ultrasound findings to decide on treatment.
When results are inconclusive, many providers schedule a multidisciplinary review with obstetricians, infectious‑disease specialists, and perinatal psychologists. This collaborative approach ensures that you receive both medical clarity and emotional support.
Managing a positive IgM: treatment options and follow‑up care
If your combined testing indicates fetal infection, the primary goal is to limit parasite replication and protect the developing brain and eyes. The two main drug regimens, endorsed by CDC and WHO, are:
In addition to medication, your provider will schedule more frequent ultrasounds (often every 2–3 weeks) to track disease progression. Some centers also offer neonatal serology and ophthalmologic exams after birth to catch any late‑appearing complications.
Medication side‑effects are a common concern. Spiramycin is generally well‑tolerated, but a small percentage of patients report mild gastrointestinal upset. The pyrimethamine‑based regimen can cause transient drops in white‑blood‑cell counts, so weekly blood draws are standard until levels stabilize.
Even if you’re not infected, the process of testing can be emotionally draining. It’s helpful to enlist a support person for appointments, keep a symptom diary, and discuss any mental‑health concerns with your provider. Many hospitals have counseling services for pregnant patients navigating complex prenatal testing.
For those who want to estimate their personal risk based on exposure timing and test results, the Congenital Infection Workup calculator offers a quick, evidence‑based assessment that can be discussed with your obstetrician.
Reducing the risk of toxoplasmosis during pregnancy
Prevention is the most powerful tool. Here are evidence‑based habits endorsed by the CDC and WHO:
- Cook meat thoroughly: Heat to at least 165 °F (74 °C) for ground meat, and 145 °F (63 °C) with a three‑minute rest for whole cuts.
- Avoid raw or unpasteurized dairy: Even soft cheeses can harbor the parasite.
- Handle cat litter carefully: Change litter daily, wear gloves, and wash hands afterward. If possible, let someone else clean the box.
- Wash fruits and vegetables: Rinse under running water; scrub firm produce with a brush.
- Wear gloves when gardening: Soil can be contaminated; gloves and hand‑washing reduce exposure.
These steps cut the odds of primary infection dramatically—studies suggest a 50 % reduction in seroconversion among pregnant women who follow strict hygiene practices.
In addition to hygiene, consider nutritional support. Adequate vitamin C intake (from citrus fruits or bell peppers) may enhance immune clearance of the parasite, although definitive data are limited. Discuss any supplement plans with your provider to avoid interactions with antiparasitic medications.
Understanding the timeline of infection and fetal transmission
The gestational age at which a primary T. gondii infection occurs is the single biggest predictor of fetal outcome. In the first trimester, the placenta is more permissive, and the fetus is most vulnerable to severe neurologic damage. By the third trimester, the placenta becomes less permeable, and while transmission rates rise, the fetus is better able to tolerate the parasite.
Research from the WHO shows that the risk of fetal infection rises from roughly 10 % in the first 12 weeks to 50 % after 30 weeks. However, the severity of disease tends to decrease as gestation advances. This paradox underscores why early detection—through IgM, avidity, and PCR—is crucial: it informs both the timing of treatment and realistic counseling about possible outcomes.
If infection occurs after 20 weeks, many clinicians still recommend spiramycin to limit further transmission, followed by close ultrasound monitoring. The decision to switch to the pyrimethamine‑based regimen is usually based on a positive PCR or the appearance of fetal abnormalities on imaging.
Emotional support and counseling resources
Receiving a positive IgM can feel isolating, but you are not alone. Many hospitals offer perinatal mental‑health services that specialize in anxiety related to prenatal testing. A brief session with a therapist trained in obstetric care can provide coping strategies, such as grounding techniques and structured worry‑time, which have been shown to reduce pregnancy‑related anxiety.
Support groups—both in‑person and online—can also be a lifeline. Organizations like the American Pregnancy Association host moderated forums where parents share experiences of navigating toxoplasmosis testing. Connecting with someone who has walked a similar path often turns vague fear into concrete, manageable steps.
Don’t hesitate to ask your obstetrician for a referral to a social worker or psychologist. The American College of Obstetricians and Gynecologists recommends integrating psychosocial assessment into any high‑risk pregnancy care plan.
What to ask your provider during follow‑up appointments
Having a list of questions ready can make your appointments feel more productive. Consider asking:
- “What does my avidity index tell us about the timing of infection?”
- “If PCR is negative now, will we repeat it later?”
- “What are the specific ultrasound findings we’re watching for?”
- “Can you explain the benefits and risks of spiramycin versus pyrimethamine‑based therapy?”
- “How often should I schedule ultrasounds, and can I have the same sonographer each time?”
- “What signs should prompt me to call you right away?”
Writing these questions down ahead of time helps you stay focused, especially when emotions run high. Bring a partner or trusted friend to the visit—they can help remember details and provide emotional support.
When to consider amniocentesis: timing and safety
Amniocentesis is the most direct way to obtain amniotic fluid for PCR testing, but it is an invasive procedure. Current ACOG guidance recommends it when the combination of a low‑avidity IgM result and clinical suspicion suggests a meaningful risk of fetal infection, typically after 16 weeks gestation. Performing the test earlier than 16 weeks can reduce the sensitivity of PCR, while waiting beyond 20 weeks may limit therapeutic options.
The procedure carries a small risk of miscarriage—estimated at 0.1–0.3 % in experienced hands. Ultrasound guidance, a sterile technique, and an experienced operator minimize this risk. Your provider will discuss your individual risk factors (such as uterine anomalies or a history of preterm birth) before recommending amniocentesis. If you decline, serial ultrasounds and possibly cord‑blood PCR after delivery become the alternative monitoring strategy.
Nutrition and supplements during treatment
While antiparasitic drugs are the cornerstone of therapy, nutrition can support both maternal health and fetal development. A balanced diet rich in lean protein, whole grains, and colorful vegetables supplies the nutrients needed for immune function. Folinic acid (leucovorin) is routinely co‑prescribed with pyrimethamine to mitigate bone‑marrow suppression; ensure you take it exactly as directed.
Supplemental iron and vitamin B12 are often needed in pregnancy, but avoid high‑dose zinc or copper supplements unless a deficiency is documented, as excess minerals can interfere with drug absorption. If you are taking a prenatal multivitamin, confirm with your provider that it does not contain ingredients that could diminish the effectiveness of spiramycin or pyrimethamine.
Long‑term follow‑up after birth
Even after a successful pregnancy, infants exposed to T. gondii should be monitored for delayed sequelae. The CDC recommends serologic testing at birth, 1 month, and 12 months, along with a comprehensive ophthalmologic exam to detect chorioretinitis. Neurodevelopmental assessments at 6 and 12 months help identify subtle motor or cognitive delays that may benefit from early intervention.
If the newborn tests positive, a pediatric infectious‑disease specialist may continue a shortened course of pyrimethamine‑based therapy, adjusted for the infant’s weight and renal function. Ongoing follow‑up with a pediatric neurologist and ophthalmologist ensures any emerging issues are caught early, maximizing the child’s chances for normal development.
From our medical team: A positive IgM result can feel like a cliff edge, but remember that the diagnostic pathway is designed to separate true infections from false alarms. Most women with low‑avidity results receive treatment that dramatically reduces fetal risk, and many pregnancies continue without complications. Keep close communication with your obstetrician, ask for clarification whenever a term feels unfamiliar, and lean on your support network for emotional steadiness.
Myth vs. fact
Myth: A positive IgM always means the baby is infected.
Fact: IgM indicates recent exposure, but follow‑up avidity testing, PCR, and ultrasound are needed to determine fetal infection.
Myth: If the PCR is negative, the baby is definitely safe.
Fact: PCR is highly specific, yet a negative result early in pregnancy may miss low‑level infection; ongoing ultrasound monitoring remains essential.
Myth: You must stop all cat exposure permanently during pregnancy.
Fact: Safe cat handling (daily litter changes, gloves, hand washing) can prevent transmission without eliminating all contact.
Key takeaways
- Positive IgM signals recent exposure; it’s not a final diagnosis.
- Avidity testing tells you how recent the infection likely is—low avidity = recent, high avidity = older.
- PCR on amniotic fluid is the most reliable way to confirm fetal infection.
- Targeted ultrasounds every 4 weeks (or more often if PCR‑positive) monitor fetal health.
- Even with a positive IgM, treatment with spiramycin or pyrimethamine‑sulfadiazine can markedly lower fetal risk.
- Simple hygiene steps—cooking meat thoroughly, washing produce, careful cat litter handling—greatly reduce infection odds.
- Emotional support, clear communication, and a written question list empower you throughout the process.
- Post‑birth monitoring of the infant’s eye and neurodevelopment is essential for early detection of delayed effects.
Frequently asked questions
What does a positive IgM test mean in pregnancy?
A positive IgM indicates a recent exposure to Toxoplasma gondii, but it does not confirm fetal infection; further testing with avidity, PCR, and ultrasound is required to assess risk.
How accurate is avidity testing for toxoplasmosis?
Avidity testing is highly specific (> 95 %) for distinguishing recent from past infection, though its sensitivity can be affected by individual immune variations; it is most reliable when combined with PCR and imaging.
What is the purpose of PCR testing in pregnancy?
PCR detects parasite DNA directly in amniotic fluid, providing a definitive answer about fetal infection; a positive result confirms transmission, while a negative result reduces—but does not entirely eliminate—the likelihood of infection.
Can a positive IgM test cause miscarriage?
The IgM itself does not cause miscarriage; however, primary toxoplasmosis infection can increase the risk of fetal complications, which in severe cases may lead to miscarriage. Prompt treatment and monitoring can mitigate this risk.
How often should I have ultrasound surveillance after a positive IgM test?
Guidelines recommend a detailed anatomy scan at 18–20 weeks, followed by targeted scans every 4 weeks until 30 weeks, and a final scan at 34–36 weeks, with more frequent imaging if PCR is positive or abnormalities appear.
What are the risks of toxoplasmosis to my unborn baby?
Fetal infection can lead to hydrocephalus, intracranial calcifications, chorioretinitis, growth restriction, and, in severe cases, stillbirth. Early detection and treatment dramatically reduce the likelihood of these outcomes.
Can I breastfeed while being treated for toxoplasmosis?
Spiramycin is considered safe during lactation, and most guidelines allow breastfeeding while on this medication. Pyrimethamine‑based regimens are usually avoided until after delivery because pyrimethamine can cross into breast milk; your provider will tailor therapy accordingly.
Is there a vaccine for toxoplasmosis?
Currently, no vaccine is approved for human use. Research is ongoing, and experimental vaccines have shown promise in animal models, but prevention remains focused on hygiene and early detection.
What should I do if my PCR result is inconclusive?
If PCR yields an indeterminate result, your provider will likely repeat the test later in pregnancy and increase the frequency of ultrasound monitoring. In many cases, a combination of rising avidity indices and stable ultrasound findings can provide reassurance while the repeat PCR clarifies infection status.
Can I travel during the monitoring period?
Travel is generally safe, but you should avoid high‑risk activities such as eating undercooked meat, drinking untreated water, or handling cat litter in unfamiliar settings. Discuss any upcoming trips with your obstetrician so they can advise on precautions and whether any additional testing is needed before you depart.
When to call your doctor
If you experience any of the following, contact your obstetrician or midwife immediately: fever > 100.4 °F (38 °C), severe headache, visual changes, sudden swelling of the hands or face, vaginal bleeding, or a rapid decrease in fetal movement. This article provides general information and is not a substitute for personalized medical advice.
References
- Centers for Disease Control and Prevention. “Toxoplasmosis: Pregnancy.” CDC website, 2023.
- American College of Obstetricians and Gynecologists. “Management of Toxoplasmosis in Pregnancy.” ACOG Practice Bulletin No. 194, 2022.
- National Institute for Health and Care Excellence. “Toxoplasmosis in Pregnancy.” NICE Clinical Guideline CG191, 2021.
- World Health Organization. “Congenital Toxoplasmosis: Guidelines for Prevention, Diagnosis, and Treatment.” WHO Publication, 2020.
- Mayo Clinic. “Toxoplasmosis – Symptoms and Causes.” Mayo Clinic, 2023.
- U.S. Food and Drug Administration. “Spiramycin and Pyrimethamine: Use in Pregnancy.” FDA Drug Safety Communication, 2022.
- National Center for Biotechnology Information. “PCR Sensitivity for Toxoplasma gondii in Amniotic Fluid.” NCBI Review, 2021.
- British Pregnancy Advisory Service. “Ultrasound Monitoring of Congenital Infections.” BPAS Guidelines, 2022.
- Royal College of Obstetricians and Gynaecologists. “Infection in Pregnancy.” RCOG Guideline, 2022.
- American Pregnancy Association. “Support Resources for High‑Risk Pregnancy.” APA Resource List, 2023.
